{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T14:20:58Z","timestamp":1763389258039,"version":"3.37.3"},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T00:00:00Z","timestamp":1571184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006477","name":"National Taiwan University","doi-asserted-by":"crossref","award":["NTUH.106-P01"],"award-info":[{"award-number":["NTUH.106-P01"]}],"id":[{"id":"10.13039\/501100006477","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0223972","type":"journal-article","created":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T20:03:02Z","timestamp":1571256182000},"page":"e0223972","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":26,"title":["Involution of retinopathy of prematurity and neurodevelopmental outcomes after intravitreal bevacizumab treatment"],"prefix":"10.1371","volume":"14","author":[{"given":"Yu-Shan","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying-Tin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tso-Ting","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hung-Chieh","family":"Chou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wu-Shiun","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chung-May","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0461-8778","authenticated-orcid":true,"given":"Po-Ting","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6114-1769","authenticated-orcid":true,"given":"Po-Nien","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2019,10,16]]},"reference":[{"issue":"3","key":"pone.0223972.ref001","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1542\/peds.104.3.e26","article-title":"Current incidence of retinopathy of prematurity, 1989\u20131997","volume":"104","author":"N Hussain","year":"1999","journal-title":"Pediatrics"},{"issue":"11","key":"pone.0223972.ref002","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/S0161-6420(91)32074-8","article-title":"Incidence and early course of retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group","volume":"98","author":"EA Palmer","year":"1991","journal-title":"Ophthalmology"},{"issue":"4","key":"pone.0223972.ref003","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1542\/peds.2004-1309","article-title":"Prenatal risk factors for severe retinopathy of prematurity among very preterm infants of the Australian and New Zealand Neonatal Network","volume":"115","author":"BA Darlow","year":"2005","journal-title":"Pediatrics"},{"issue":"3","key":"pone.0223972.ref004","doi-asserted-by":"crossref","first-page":"F240","DOI":"10.1136\/adc.2004.057570","article-title":"UK population based study of severe retinopathy of prematurity: screening, treatment, and outcome","volume":"90","author":"L Haines","year":"2005","journal-title":"Archives of disease in childhood Fetal and neonatal edition"},{"issue":"4","key":"pone.0223972.ref005","doi-asserted-by":"crossref","first-page":"F251","DOI":"10.1136\/adc.2006.096479","article-title":"Severe retinopathy of prematurity in infants <30 weeks' gestation in New South Wales and the Australian Capital Territory from 1992 to 2002","volume":"92","author":"DA Todd","year":"2007","journal-title":"Archives of disease in childhood Fetal and neonatal edition"},{"key":"pone.0223972.ref006","first-page":"233","article-title":"Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial","volume":"102","author":"WV Good","year":"2004","journal-title":"Transactions of the American Ophthalmological Society"},{"issue":"1","key":"pone.0223972.ref007","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1542\/peds.2012-2996","article-title":"Screening examination of premature infants for retinopathy of prematurity","volume":"131","author":"American Academy of Pediatrics Section on O, American Academy of O, American Association for Pediatric O, Strabismus, American Association of Certified O","year":"2013","journal-title":"Pediatrics"},{"issue":"11","key":"pone.0223972.ref008","first-page":"1727","article-title":"for aggressive zone I retinopathy of prematurity. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle","volume":"245","author":"EJ Chung","year":"2007","journal-title":"Ophthalmologie"},{"issue":"7","key":"pone.0223972.ref009","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"HA Mintz-Hittner","year":"2011","journal-title":"The New England journal of medicine"},{"issue":"9","key":"pone.0223972.ref010","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/eye.2014.172","article-title":"Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes","volume":"28","author":"YH Chen","year":"2014","journal-title":"Eye"},{"issue":"12","key":"pone.0223972.ref011","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial","volume":"121","year":"2003","journal-title":"Archives of ophthalmology"},{"issue":"6","key":"pone.0223972.ref012","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1097\/IAE.0b013e3181a3b7b1","article-title":"Transconjunctival, sutureless 25-gauge lens sparing vitrectomy for stage 4 retinopathy of prematurity-related retinal detachments","volume":"29","author":"BT Chan-Kai","year":"2009","journal-title":"Retina"},{"issue":"3","key":"pone.0223972.ref013","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/eye.2015.289","article-title":"Involution patterns of retinopathy of prematurity after treatment with intravitreal bevacizumab: implications for follow-up","volume":"30","author":"M Isaac","year":"2016","journal-title":"Eye"},{"issue":"3","key":"pone.0223972.ref014","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1167\/iovs.09-4140","article-title":"Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes","volume":"51","author":"T Miyake","year":"2010","journal-title":"Investigative ophthalmology & visual science"},{"issue":"5","key":"pone.0223972.ref015","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","article-title":"Pharmacokinetics of intravitreal bevacizumab (Avastin).","volume":"114","author":"SJ Bakri","year":"2007","journal-title":"Ophthalmology"},{"issue":"6","key":"pone.0223972.ref016","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1242\/dev.126.6.1149","article-title":"VEGF is required for growth and survival in neonatal mice","volume":"126","author":"HP Gerber","year":"1999","journal-title":"Development"},{"issue":"4","key":"pone.0223972.ref017","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/sj.jcbfm.9600573","article-title":"Coupling of angiogenesis and neurogenesis in cultured endothelial cells and neural progenitor cells after stroke","volume":"28","author":"H Teng","year":"2008","journal-title":"Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism"},{"issue":"3","key":"pone.0223972.ref018","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0006-2952(00)00529-3","article-title":"Angiogenesis: regulators and clinical applications","volume":"61","author":"S Liekens","year":"2001","journal-title":"Biochemical pharmacology"},{"issue":"4","key":"pone.0223972.ref019","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2015-3218","article-title":"Neurodevelopmental Outcomes Following Bevacizumab Injections for Retinopathy of Prematurity","volume":"137","author":"J Morin","year":"2016","journal-title":"Pediatrics"},{"issue":"1","key":"pone.0223972.ref020","doi-asserted-by":"crossref","first-page":"e0148019","DOI":"10.1371\/journal.pone.0148019","article-title":"Neurodevelopmental Outcomes in Infants with Retinopathy of Prematurity and Bevacizumab Treatment","volume":"11","author":"R Lien","year":"2016","journal-title":"PloS one"},{"issue":"6","key":"pone.0223972.ref021","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3109\/02713683.2014.941070","article-title":"Preliminary anatomical and neurodevelopmental outcomes of intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity","volume":"40","author":"B Araz-Ersan","year":"2015","journal-title":"Current eye research"},{"issue":"2","key":"pone.0223972.ref022","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/IAE.0b013e318275394a","article-title":"Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up","volume":"33","author":"MA Martinez-Castellanos","year":"2013","journal-title":"Retina"},{"issue":"1","key":"pone.0223972.ref023","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jaapos.2017.10.006","article-title":"Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity","volume":"22","author":"KA Kennedy","year":"2018","journal-title":"Journal of AAPOS: the official publication of the American Association for Pediatric Ophthalmology and Strabismus \/ American Association for Pediatric Ophthalmology and Strabismus"},{"issue":"9","key":"pone.0223972.ref024","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1097\/IAE.0000000000000535","article-title":"PLASMA CONCENTRATIONS OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN RETINOPATHY OF PREMATURITY AFTER INTRAVITREAL BEVACIZUMAB INJECTION","volume":"35","author":"YR Hong","year":"2015","journal-title":"Retina"},{"issue":"2","key":"pone.0223972.ref025","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1167\/iovs.14-15842","article-title":"Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity","volume":"56","author":"L Kong","year":"2015","journal-title":"Investigative ophthalmology & visual science"},{"issue":"4","key":"pone.0223972.ref026","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/jamaophthalmol.2014.5373","article-title":"Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity","volume":"133","author":"WC Wu","year":"2015","journal-title":"JAMA ophthalmology"},{"issue":"3","key":"pone.0223972.ref027","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00417-017-3878-4","article-title":"Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity","volume":"256","author":"CY Huang","year":"2018","journal-title":"Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie"},{"issue":"4","key":"pone.0223972.ref028","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/IAE.0000000000001209","article-title":"SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER BEVACIZUMAB OR RANIBIZUMAB TREATMENT FOR RETINOPATHY OF PREMATURITY","volume":"37","author":"WC Wu","year":"2017","journal-title":"Retina"},{"issue":"1\u20131","key":"pone.0223972.ref029","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/pr.2015.181","article-title":"Serum concentrations of vascular endothelial growth factor in relation to retinopathy of prematurity","volume":"79","author":"G Hellgren","year":"2016","journal-title":"Pediatric research"},{"issue":"6","key":"pone.0223972.ref030","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1001\/jamaophthalmol.2017.1055","article-title":"Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity: A Phase 1 Dosing Study","volume":"135","author":"DK Wallace","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"pone.0223972.ref031","article-title":"A Dosing Study of Bevacizumab for Retinopathy of Prematurity: Late Recurrences and Additional Treatments","author":"DK Wallace","year":"2018","journal-title":"Ophthalmology"},{"issue":"7","key":"pone.0223972.ref032","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1136\/bjophthalmol-2012-302276","article-title":"Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity","volume":"97","author":"MA Castellanos","year":"2013","journal-title":"The British journal of ophthalmology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0223972","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T23:04:39Z","timestamp":1664665479000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0223972"}},"subtitle":[],"editor":[{"given":"Ronald Mark","family":"Hansen","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,10,16]]},"references-count":32,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,10,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0223972","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2019,10,16]]}}}